Basic Science and Pathogenesis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's Disease (AD) is characterized by chronic neuroinflammation.
• Toll-like receptors (TLRs), particularly TLR4, exacerbate neurodegeneration via inflammatory cascades.
• The role of TLR4 in AD pathogenesis necessitates investigation into therapeutic modulators.

Purpose of the Study:

• To evaluate the impact of chronic lithium treatment on neuroinflammatory pathways in a 3xTg-AD mouse model.
• To investigate lithium's effect on Toll-like receptor (TLR) signaling and associated inflammatory markers.

Main Methods:

• Administered chronic lithium (1 mM and 2 mM) to 3xTg-AD and Wild-Type (WT) mice for 8 months.
• Analyzed hippocampal proteomes using LC-MS/MS and identified proteins via MaxQuant.
• Performed functional, ontological, and protein interaction network analyses using Cytoscape, STRING, and BINGO; statistical significance determined by two-way ANOVA with Benjamini-Hochberg correction (p < 0.05).

Main Results:

• Identified 2,807 proteins; 932 were exclusive to lithium-treated 3xTg-AD mice.
• Observed significant reductions in TLR4 (p=0.003) and IL-1β (p=0.005) with 2 mM lithium treatment.
• Protein interaction networks revealed TLR4 and MAPK1 as central hubs in inflammatory modulation and stress response, linking lithium to direct interference with AD-associated inflammatory signaling.

Conclusions:

• Chronic lithium treatment effectively modulated neuroinflammation in 3xTg-AD mice.
• Lithium reduced pro-inflammatory markers (TLR4, IL-1β) and reorganized molecular networks involved in TLR signaling.
• Findings support lithium's potential as a therapeutic agent for Alzheimer's Disease, warranting further clinical investigation.